Browse the evidence

Pioglitazone improves MASH resolution and may improve fibrosis, but is limited by side effects like weight gain and heart failure exacerbation.

Pioglitazone can resolve MASH and improve fibrosis, but it causes weight gain and fluid retention, which can worsen heart failure. It is not a first-line treatment but may be considered if other options fail and heart failure is not a concern.

Once-weekly semaglutide treatment is associated with a significant increase in pulse rate compared to once-daily sitagliptin.

If you take semaglutide, expect your resting heart rate to increase slightly (by about 3 beats per minute) compared to if you took sitagliptin. This is a known side effect. While usually not dangerous, it is worth monitoring, especially if you have underlying heart conditions.

Semaglutide treatment is associated with a higher risk of total adverse events and premature treatment discontinuation compared to sitagliptin, although the risk of serious adverse events is not significantly different.

Be prepared for a higher likelihood of side effects and stopping the medication early when starting semaglutide compared to sitagliptin. Most side effects are gastrointestinal. Slow dose escalation can help. However, serious adverse events are not significantly more common with semaglutide.

GLP-1 receptor agonists increase the risk of gallbladder disease, including cholelithiasis and cholecystitis, through mechanisms involving cholecystokinin (CCK) suppression, altered bile acid receptor signaling (FXR/TGR5), and disrupted gut-brain pathways, leading to bile stasis and gallstone formation.

If you are taking a GLP-1 agonist (like semaglutide or liraglutide), be aware that you have a higher risk of gallbladder problems, especially if you are taking higher doses or losing weight rapidly. Watch for symptoms like severe abdominal pain, nausea, or fever, and report them to your doctor immediately. Your doctor may monitor you more closely or adjust your treatment plan to mitigate this risk.

Activation of brown and beige adipose tissue through pharmacological means (e.g., β3-AR agonists, GLP-1RAs) or transplantation improves glucose metabolism, insulin sensitivity, and energy expenditure, offering a therapeutic strategy for obesity and type 2 diabetes.

Your body has a biological mechanism to burn extra energy as heat using brown and beige fat. While cold exposure and exercise can activate this, pharmaceutical approaches (like mirabegron or GLP-1 agonists) are being studied to enhance this process. This suggests that metabolic health is not just about calories in/out but also about the activity of specific fat tissues.

Biased agonism of GLP-1R and GIPR (favoring cAMP over beta-arrestin recruitment) yields superior glucose lowering, food intake suppression, and weight loss compared to unbiased agonism.

Current GLP-1/GIP drugs that favor cAMP signaling (biased) appear to offer better and longer-lasting glucose control and weight loss than those that do not. This is likely due to the drug staying on the receptor longer without being internalized. While this is proven in mice, it suggests that drug design matters for efficacy, not just receptor activation.

AgRP neuron inhibition is a necessary mechanism for the appetite-suppressing effects of incretin-based obesity therapies (GLP-1 and GIP analogs).

This research confirms that GLP-1 and GIP medications (like Ozempic or Wegovy) work by directly inhibiting the brain's hunger-promoting neurons (AgRP). This neural inhibition is a key reason these drugs successfully suppress appetite.

GIP signaling is necessary for nutrient-mediated inhibition of AgRP neurons, whereas GLP-1 signaling is not.

This study reveals that GIP, not just GLP-1, is essential for your brain to register that you have eaten. This explains why drugs that activate both receptors (like Mounjaro/Zepbound) may be more effective than those activating only GLP-1.

GIPR signaling in the central nervous system (specifically GABAergic neurons) is required for the body weight-lowering effects of GIP-based therapies, whereas peripheral GIPR signaling in adipose tissue has complex, context-dependent effects on lipolysis vs lipogenesis.

GIP-based drugs work primarily by acting on the brain to reduce food intake, not just by affecting fat cells. This brain-based mechanism is why they are effective for weight loss even in non-diabetic individuals.

Dietary macronutrient composition (low-carbohydrate vs. low-fat) does not explain differences in ad libitum energy intake because the resulting changes in gut-derived appetite hormones (GLP-1, GIP, PYY, ghrelin) are insufficient to override other dietary factors like energy density and hyper-palatability.

Don't rely on low-carb or low-fat diets to magically regulate your hunger through hormones. This study shows that even when hormones change significantly, they don't dictate how much you eat if other factors like energy density and taste are present. Focus on the physical properties of food (volume, density) rather than just the macronutrient ratio for short-term intake control.

GLP-1 administration (25 nmol/kg) significantly augments glucose-stimulated insulin secretion and improves glucose tolerance in mice, whereas GLP-2 (25 nmol/kg) improves glucose tolerance without directly augmenting insulin secretion.

Both GLP-1 and GLP-2 peptides improve blood glucose levels in mice, but they do so through different biological pathways. GLP-1 works by telling beta cells to release more insulin, while GLP-2 improves glucose handling without directly increasing insulin secretion. This suggests that targeting GLP-2 receptors could be a viable strategy for glucose control that avoids potential side effects of excessive insulin secretion.

Both GLP-1 and GLP-2 suppress appetite and reduce food intake in mice, regardless of their differential effects on insulin secretion.

Both GLP-1 and GLP-2 peptides reduce food intake in mice, suggesting that GLP-2 could be used to manage appetite without necessarily stimulating insulin secretion. This makes GLP-2 a potential candidate for obesity treatment where insulin secretion is not desired.

Both GLP-1 and GLP-2 promote beta-cell proliferation and protect against cytokine-induced apoptosis, preserving beta-cell mass and function.

Both GLP-1 and GLP-2 help protect beta-cells from death and promote their growth. This suggests that GLP-2 could be used to preserve beta-cell mass in diabetes, potentially slowing disease progression.

Naltrexone/Bupropion is not recommended for individuals with obesity and established atherosclerotic cardiovascular disease (ASCVD) or heart failure (HF) due to potential hemodynamic stress and lack of outcome data.

If you have obesity and established heart disease or heart failure, naltrexone/bupropion is not recommended because it can increase heart rate and blood pressure, potentially worsening your condition. Safer, proven alternatives are available.

Semaglutide, despite achieving NASH resolution, failed to improve fibrosis stage in phase 2 trials, highlighting a gap in treating advanced fibrosis compared to resmetirom.

Semaglutide helps resolve NASH but does not improve fibrosis. Patients with advanced fibrosis should consider other options like resmetirom.

Obeticholic acid (OCA) trials for NASH were discontinued due to safety concerns and modest efficacy, despite showing some histological improvement.

Obeticholic acid is not approved for NASH due to safety issues.

Lixisenatide and high-dose efpeglenatide (6 mg/week) are associated with a statistically significant increase in hearing loss events compared to controls, whereas other GLP-1 receptor agonists and SGLT2 inhibitors do not demonstrate this elevated risk.

If you are taking Lixisenatide or high-dose Efpeglenatide, be aware of a potential increased risk of hearing loss. This risk is not seen with other GLP-1 drugs like Semaglutide or Dulaglutide in this analysis. Report any sudden hearing changes to your doctor immediately, but do not stop your medication without consulting them, as the absolute risk (NHH ~757) is relatively low.

Current NuSH trials rarely assess bone health, despite the known risk of bone mass reduction associated with significant weight loss.

If you are on NuSHs, ask your doctor about bone density scans, especially if you are post-menopausal or elderly. Ensure adequate calcium and vitamin D intake, as weight loss can compromise bone strength.

Biological mechanisms, specifically a defended weight set point driven by genetic and epigenetic factors, actively oppose weight loss maintenance by altering hunger hormones and reducing energy expenditure, making long-term weight loss difficult without continuous intervention.

Accept that maintaining weight loss is biologically harder than losing it due to hormonal defenses. Do not rely on short-term diets; instead, focus on long-term strategies like preventing 'weight creep' (0.5-1kg/year gain) through low-intensity lifestyle changes or considering long-term pharmacological support (like GLP-1 agonists or metformin) if indicated, rather than expecting a one-time fix.

Protein restriction (specifically low-protein, high-carbohydrate diets) extends lifespan and improves metabolic health in model organisms, likely through mechanisms distinct from or overlapping with calorie restriction, such as elevated FGF21.

In model organisms, restricting protein (while keeping calories normal) extends lifespan and improves metabolic health, partly by boosting FGF21. However, this comes at the cost of muscle mass. For humans, high protein is generally recommended for muscle maintenance, but excessive intake might increase mortality risk. The optimal protein intake likely balances longevity benefits with the need to preserve physical resilience, suggesting a moderate approach rather than extreme restriction or excess.

Activation of Glucagon-Like Peptide-1 Receptors (GLP-1R) in the Gustatory Cortex (GC) reduces homeostatic food intake in mice.

This research identifies a specific brain region (Gustatory Cortex) where GLP-1 receptors are active and influence how much we eat. While this doesn't change current dietary advice, it explains part of the mechanism behind GLP-1 based weight loss drugs, suggesting they work by altering how the brain processes taste and hunger signals, not just by signaling fullness from the gut.

The effect of GC GLP-1R activation on food intake is conditional on the palatability and fat content of the food, particularly in mice chronically maintained on a high-fat diet.

If you are trying to lose weight, switching from a high-fat diet to a lower-fat diet might make appetite-suppressing medications (like GLP-1 agonists) more effective. The brain's response to these drugs seems to depend on the palatability of the food, and changing your diet may help reset these signals.

GIPR agonism in humans may not provide weight loss benefits and can negate the appetite-suppressing effects of GLP-1.

While GIPR agonists work in animals, human studies show that adding GIP to GLP-1 can actually stop GLP-1 from working as well for appetite control. This suggests the human body responds differently than mice.

DPP-4 inhibitors (specifically Saxagliptin and Alogliptin) may increase the risk of hospitalization for heart failure, whereas Sitagliptin and Linagliptin appear neutral.

If you have Type 2 Diabetes and Heart Failure, be cautious with DPP-4 inhibitors. Saxagliptin and Alogliptin have been linked to an increased risk of heart failure hospitalization. However, Sitagliptin and Linagliptin have shown neutral effects. Discuss the specific risks and benefits with your doctor to choose the safest option for your heart.